E-cadherin (CDH1) is a tumor suppressor involved in epithelial cell-cell interactions. Single nucleotide polymorphisms (SNP) in the CDH1 gene, -160C/A and -347G/GA in the 5'-promoter region and +54C/T in the 3'-untranslated region (UTR) have been shown to be associated with tumor development and progression via modifying transcriptional activity, mRNA stability or protein expression. To investigate the influence of CDH1 SNP on susceptibility to esophageal squamous cell carcinomas (ESCC) and gastric cardia adenocarcinomas (GCA), a case-control study was conducted among 333 ESCC patients, 239 GCA patients and 343 controls from a northern Chinese population. CDH1 polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism analysis. The results showed that; (i) genotypes with the +54C allele (C/C or C/T) significantly increased the risk of developing both ESCC and GCA compared to the +54T/T genotype (age and gender adjusted odds ratio [OR] = 1.45 and 2.28, 95% confidence interval [CI] = 1.06-1.99 and 1.58-3.30, respectively), and this association was significant only among non-smokers (OR = 1.68 and 2.64, 95% CI = 1.01-2.80 and 1.43-4.87 for ESCC and GCA, respectively), and individuals without a family history of upper gastrointestinal cancer (OR = 2.63 and 2.97, 95% CI = 1.36-5.10 and 95% CI = 1.32-6.68 for ESCC and GCA, respectively); (ii) compared with the -347G/G genotype, the -347GA and GA/GA genotypes significantly increased the risk of developing GCA (OR = 1.45, 95 % CI = 1.03-2.04); (iii) there was a significant association of CDH1-160C/-347G/+54C and -160C/-347GA/+54C haplotypes with the development of GCA, compared with the -160C/-347G/+54T haplotype (OR = 1.80 and 2.21, 95% CI = 1.33-2.44 and 1.43-3.42, respectively); and (iv) the influence of CDH1 SNP on the depth of tumor invasion and lymphatic metastasis in ESCC and GCA patients was not observed in this study. The present study indicates that CDH1 polymorphisms might modify susceptibility to ESCC and/or GCA.

P73, a p53 homolog, has some p53-like activities and plays an important role in modulating cell cycle, apoptosis and DNA repair. The two linked polymorphisms in the non-coding region of exon2 of p73 gene, named G4C14-A4T14, may alter translation efficiency of the gene. The transcription of p73 gene is initiated by three promoters, termed P1-P3. There is a single nucleotide substitution (-386G/A) in the P3 promoter region with unknown function. To test the hypothesis that the genetic variations in the exon2 and P3 promoter play a role in the etiology of esophageal squamous cell carcinoma (ESCC), we conducted a population-based case-control study in 348 ESCC patients and 583 healthy controls from a high incidence region of Hebei province, China. The p73 polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP). The results showed that the family history of upper gastrointestinal cancer (UGIC) significantly increased the risk of developing ESCC (the age, sex and smoking status adjusted OR = 2.02, 95% CI = 1.54-2.67). The overall distribution of the p73 genotype, allelotype and haplotype in cancer patients and controls were not significantly different (all P-values are above 0.05). Stratification analysis by smoking status and family history of UGIC also did not show the significant influence of the polymorphisms on the risk of ESCC development. The results suggested that the p73 exon2 G4C14-A4T14 and P3 promoter -386G/A polymorphisms might not be used as potential markers to predicate the risk of ESCC development in northern China.

No abstract

Background: To explore the efficiency of transvaginal ultrasonography in determining muscular infiltration of phase I endometrial cancer prognosis for radiotherapy. Materials and Methods: A total of 96 phase I endometrial cancer patients who were admitted between March 2018 and March 2020 were enrolled and transvaginal ultrasonography was applied for the diagnosis of muscular infiltration. Demographic variables and radiotherapy outcomes were recorded. We hypnotized that only patients with unfavorable profile of sonography receive pelvic radiotherapy. Results: Patients with muscular infiltration > 1/2 had much thicker endometrium than those with muscular infiltration ≤ 1/2. the sensitivity, specificity, accuracy, positive predictive value and negative predictive value of transvaginal ultrasonography in diagnosis of muscular infiltration of phase I endometrial cancer versus surgery results were 84.9%, 88.9%, 87.5%, 80.0% and 91.8%, while the consistency and Kappa value between the transvaginal ultrasonography and pathological test was 72.2% and 0.580. Positive Likelihood ratio of muscular infiltration more than 1/2 was 2.10 (CI95%: 1.22 to 3.61), meaning that approximately 10 patients of 17 patients with muscular infiltration more than ½ would experience radiotherapy later. Negative Likelihood ratio was 0.63 (CI95%: 0.44 to 0.91), meaning that approximately 10 patients of 15 patients with muscular infiltration less or equal than ½ would not experience radiotherapy later. Conclusion: Muscular infiltration of endometrial cancer in transvaginal ultrasonography could be a reliable, simple, convenient and low-cost method predicting the need for the external beam pelvic radiotherapy as an unfavorable progression in endometrial cancer.

background data. Further evaluation as phase III randomized controlled trial (RCT) was needed.Methods: We conducted a phase III multicenter RCT to elucidate the preventive effect of ED against OM in patients with esophageal cancer (EC) receiving DCF (docetaxel, cisplatin, and 5-fluorouracil) therapy. Patients were randomly assigned to receive two cycles of DCF with (group A) or without (group B) ED (160 g/day) at a 1:1 ratio. The primary endpoint was the incidence of grade 2 OM assessed using CRS by two judges. Secondary endpoints were changes in body weight, prealbumin, c-reactive protein (CRP), rate of grade 2 OM, and DCF completion rate based on ED compliance.

No abstract

No abstract

No abstract